Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Anesthesiology Reports
Published in: Current Anesthesiology Reports 4/2018

01-12-2018 | Cancer Anesthesia (B Riedel and V Gottumukkala, Section Editors)

Propofol (TIVA) Versus Volatile-Based Anesthetics: Is There Any Oncological Benefit?

Authors: Nicholas J. S. Perry, Timothy Wigmore

Published in: Current Anesthesiology Reports | Issue 4/2018

Login to get access

Abstract

Purpose of Review

To summarize the most recent available clinical and pre-clinical research data concerning the effects of propofol-based total intravenous anesthesia (TIVA) and volatile anesthesia on oncological outcomes and to discuss the biological basis by which these drugs are purported to exert effects on the cancer cell and on the host.

Recent Findings

Recent retrospective analyses of clinical datasets have generated considerable interest in the hypothesis that the two major classes of general anesthetics in clinical use for oncological surgery—namely inhalational fluranes and intravenous propofol—disparately influence post-operative cancer outcomes. There is also growing pre-clinical data to indicate that these drugs exert distinct effects on cancer cell and immune cell phenotypes.

Summary

The available evidence tends to support the superiority of propofol in terms of the effect on oncological outcomes, but there is a lack of prospective data and a need to be mindful of the complexity and heterogeneity of both the perioperative period and cancer as a disease when interpreting study results and deciding future directions.
Literature
1.
Howell SJ, Pandit JJ, Rowbotham DJ, Research Council of the National Institute of Academic A. National Institute of Academic Anaesthesia research priority setting exercise. Br J Anaesth. 2012;108(1):42–52.PubMed
2.
Shapiro J, Jersky J, Katzav S, Feldman M, Segal S. Anesthetic drugs accelerate the progression of postoperative metastases of mouse tumors. J Clin Invest. 1981;68(3):678–85.PubMedPubMedCentral
3.
Lundy J, Lovett EJ 3rd, Hamilton S, Conran P. Halothane, surgery, immunosuppression and artificial pulmonary metastases. Cancer. 1978;41(3):827–30.PubMed
4.
Biki B, Mascha E, Moriarty D, Fitzpatrick J, Sessler D, Buggy D. Anesthetic technique for radical prostatectomy surgery affects cancer recurrence: a retrospective analysis. Anesthesiology. 2008;109(2):180–7.PubMed
5.
Exadaktylos A, Buggy D, Moriarty D, Mascha E, Sessler D. Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis? Anesthesiology. 2006;105(4):660–4.PubMed
6.
•• Hiller JG, Perry NJ, Poulogiannis G, Riedel B, Sloan EK. Perioperative events influence cancer recurrence risk after surgery. Nat Rev Clin Oncol. 2018;15(4):205–18. Comprehensive up to date review of the scientific basis for a link between perioperative events and cancer outcomes PubMed
7.
Pandit JJ, Andrade J, Bogod DG, et al. 5th National Audit Project (NAP5) on accidental awareness during general anaesthesia: protocol, methods, and analysis of data. Br J Anaesth. 2014;113(4):540–8.PubMed
8.
Lim A, Braat S, Hiller J, Riedel B. Inhalational versus propofol-based total intravenous anaesthesia: practice patterns and perspectives among Australasian anaesthetists. Anaesth Intensive Care. 2018;46(5):480–7.PubMed
9.
Soltanizadeh S, Degett TH, Gogenur I. Outcomes of cancer surgery after inhalational and intravenous anesthesia: a systematic review. J Clin Anesth. 2017;42:19–25.PubMed
10.
Enlund M, Berglund A, Andreasson K, Cicek C, Enlund A, Bergkvist L. The choice of anaesthetic--sevoflurane or propofol--and outcome from cancer surgery: a retrospective analysis. Ups J Med Sci. 2014;119(3):251–61.PubMedPubMedCentral
11.
•• Wigmore TJ, Mohammed K, Jhanji S. Long-term survival for patients undergoing volatile versus IV anesthesia for cancer surgery: a retrospective analysis. Anesthesiology. 2016;124(1):69–79 Together with references 10–16 forms the clinical evidence base for the potential impact of inhalational versus propofol-based anesthesia on long-term outcomes following cancer surgery. This is the largest of the retrospective analyses, including 7030 patients undergoing surgery for cancer over a 3-year period.PubMed
12.
Lee JH, Kang SH, Kim Y, Kim HA, Kim BS. Effects of propofol-based total intravenous anesthesia on recurrence and overall survival in patients after modified radical mastectomy: a retrospective study. Korean J Anesthesiol. 2016;69(2):126–32.PubMedPubMedCentral
13.
Kim MH, Kim DW, Kim JH, Lee KY, Park S, Yoo YC. Does the type of anesthesia really affect the recurrence-free survival after breast cancer surgery? Oncotarget. 2017;8(52):90477–87.PubMedPubMedCentral
14.
Jun IJ, Jo JY, Kim JI, et al. Impact of anesthetic agents on overall and recurrence-free survival in patients undergoing esophageal cancer surgery: A retrospective observational study. Sci Rep. 2017;7(1):14020.PubMedPubMedCentral
15.
Zheng X, Wang Y, Dong L, et al. Effects of propofol-based total intravenous anesthesia on gastric cancer: a retrospective study. Onco Targets Ther. 2018;11:1141–8.PubMedPubMedCentral
16.
Oh TK, Kim K, Jheon S, et al. Long-term oncologic outcomes for patients undergoing volatile versus intravenous anesthesia for non-small cell lung Cancer surgery: a retrospective propensity matching analysis. Cancer Control. 2018;25(1):1073274818775360.PubMedPubMedCentral
17.
Melamed R, Bar-Yosef S, Shakhar G, Shakhar K, Ben-Eliyahu S. Suppression of natural killer cell activity and promotion of tumor metastasis by ketamine, thiopental, and halothane, but not by propofol: mediating mechanisms and prophylactic measures. Anesth Analg. 2003;97(5):1331–9.PubMed
18.
•• Krall JA, Reinhardt F, Mercury OA, et al. The systemic response to surgery triggers the outgrowth of distant immune-controlled tumors in mouse models of dormancy. Sci Transl Med. 2018;10(436) An experimental model that defines the means by which the inflammatory wound-healing response triggers outgrowth of anatomically distant tumors that were previously held in equilibrium. Also demonstrates a therapeutic role for NSAIDs in preventing this.
19.
20.
Friedl P, Alexander S. Cancer invasion and the microenvironment: plasticity and reciprocity. Cell. 2011;147(5):992–1009.PubMed
21.
Tavare AN, Perry NJ, Benzonana LL, Takata M, Ma D. Cancer recurrence after surgery: direct and indirect effects of anesthetic agents. Int J Cancer. 2012;130(6):1237–50.PubMed
22.
• Benzonana LL, Perry NJ, Watts HR, et al. Isoflurane, a commonly used volatile anesthetic, enhances renal cancer growth and malignant potential via the hypoxia-inducible factor cellular signaling pathway in vitro. Anesthesiology. 2013;119(3):593–605 The first study to implicate inhalational anesthetic upregulation of HIFs and associated signaling pathways with enhanced hallmarks of malignancy in vitro.PubMed
23.
Majmundar AJ, Wong WJ, Simon MC. Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell. 2010;40(2):294–309.PubMedPubMedCentral
24.
25.
Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3(10):721–32.PubMed
26.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.PubMed
27.
Schindl M, Schoppmann SF, Samonigg H, et al. Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res. 2002;8(6):1831–7.PubMed
28.
Rankin E, Giaccia A. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ. 2008;15(4):678–85.PubMed
29.
30.
Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001;292(5516):468–72.PubMed
31.
• Huang H, Benzonana LL, Zhao H, et al. Prostate cancer cell malignancy via modulation of HIF-1alpha pathway with isoflurane and propofol alone and in combination. Br J Cancer. 2014;111(7):1338–49 Further evidence of the HIF-mediated effects of an inhalational anesthetic in cancer cells which were rescued by propofol.PubMedPubMedCentral
32.
Luo X, Zhao H, Hennah L, et al. Impact of isoflurane on malignant capability of ovarian cancer in vitro. Br J Anaesth. 2014.
33.
• Shi QY, Zhang SJ, Liu L, et al. Sevoflurane promotes the expansion of glioma stem cells through activation of hypoxia-inducible factors in vitro. Br J Anaesth. 2014; Connects inhalational anesthetics with enhanced cancer stem cell phenotype.
34.
Zhu M, Li M, Zhou Y, et al. Isoflurane enhances the malignant potential of glioblastoma stem cells by promoting their viability, mobility in vitro and migratory capacity in vivo. Br J Anaesth. 2016;116(6):870–7.PubMed
35.
Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007;1(3):313–23.PubMed
36.
Samanta D, Gilkes DM, Chaturvedi P, Xiang L, Semenza GL. Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells. Proc Natl Acad Sci U S A. 2014;111(50):E5429–38.PubMedPubMedCentral
37.
Lu H, Chen I, Shimoda LA, et al. Chemotherapy-induced Ca(2+) release stimulates breast cancer stem cell enrichment. Cell Rep. 2017;18(8):1946–57.PubMed
38.
Zhang H, Lu H, Xiang L, et al. HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells. Proc Natl Acad Sci U S A. 2015;112(45):E6215–23.PubMedPubMedCentral
39.
Qin J, Liu Y, Lu Y, et al. Hypoxia-inducible factor 1 alpha promotes cancer stem cells-like properties in human ovarian cancer cells by upregulating SIRT1 expression. Sci Rep. 2017;7(1):10592.PubMedPubMedCentral
40.
• Iwasaki M, Zhao H, Jaffer T, et al. Volatile anaesthetics enhance the metastasis related cellular signalling including CXCR2 of ovarian cancer cells. Oncotarget. 2016;7(18):26042–56 Side-by-side comparison of metastasis-associated gene expression changes following exposure to the three commonest inhalational anesthetics in clinical practice today.PubMedPubMedCentral
41.
Zhang L, Zhang J, Yang L, Dong Y, Zhang Y, Xie Z. Isoflurane and sevoflurane increase interleukin-6 levels through the nuclear factor-kappa B pathway in neuroglioma cells. Br J Anaesth. 2013;110(Suppl 1):i82–91.PubMedPubMedCentral
42.
Karin M. Nuclear factor-kappaB in cancer development and progression. Nature. 2006;441(7092):431–6.PubMed
43.
Li Z, Ni C, Xia C, et al. Calcineurin/nuclear factor-kappaB signaling mediates isoflurane-induced hippocampal neuroinflammation and subsequent cognitive impairment in aged rats. Mol Med Rep. 2017;15(1):201–9.PubMed
44.
Qiao S, Xie H, Wang C, Wu X, Liu H, Liu C. Delayed anesthetic preconditioning protects against myocardial infarction via activation of nuclear factor-kappaB and upregulation of autophagy. J Anesth. 2013;27(2):251–60.PubMed
45.
Chen CH, Chuang JH, Liu K, Chan JY. Nitric oxide triggers delayed anesthetic preconditioning-induced cardiac protection via activation of nuclear factor-kappaB and upregulation of inducible nitric oxide synthase. Shock. 2008;30(3):241–9.PubMed
46.
Xuan YT, Tang XL, Banerjee S, et al. Nuclear factor-kappaB plays an essential role in the late phase of ischemic preconditioning in conscious rabbits. Circ Res. 1999;84(9):1095–109.PubMed
47.
48.
Deegan C, Murray D, Doran P, Ecimovic P, Moriarty D, Buggy D. Effect of anaesthetic technique on oestrogen receptor-negative breast cancer cell function in vitro. Br J Anaesth. 2009;103(5):685–90.PubMed
49.
Ciechanowicz S, Zhao H, Chen Q, et al. Differential effects of sevoflurane on the metastatic potential and chemosensitivity of non-small-cell lung adenocarcinoma and renal cell carcinoma in vitro. Br J Anaesth. 2018;120(2):368–75.PubMed
50.
Liang H, Gu M, Yang C, Wang H, Wen X, Zhou Q. Sevoflurane inhibits invasion and migration of lung cancer cells by inactivating the p38 MAPK signaling pathway. J Anesth. 2012;26(3):381–92.PubMed
51.
Larsen B, Seitz A, Larsen R. Recovery of cognitive function after remifentanil-propofol anesthesia: a comparison with desflurane and sevoflurane anesthesia. Anesth Analg. 2000;90(1):168–74.PubMed
52.
Hofer CK, Zollinger A, Buchi S, et al. Patient well-being after general anaesthesia: a prospective, randomized, controlled multi-centre trial comparing intravenous and inhalation anaesthesia. Br J Anaesth. 2003;91(5):631–7.PubMed
53.
Lee WK, Kim MS, Kang SW, Kim S, Lee JR. Type of anaesthesia and patient quality of recovery: a randomized trial comparing propofol-remifentanil total i.v. anaesthesia with desflurane anaesthesia. Br J Anaesth. 2015;114(4):663–8.PubMed
54.
Sneyd JR, Carr A, Byrom WD, Bilski AJ. A meta-analysis of nausea and vomiting following maintenance of anaesthesia with propofol or inhalational agents. Eur J Anaesthesiol. 1998;15(4):433–45.PubMed
55.
Kumar G, Stendall C, Mistry R, Gurusamy K, Walker D. A comparison of total intravenous anaesthesia using propofol with sevoflurane or desflurane in ambulatory surgery: systematic review and meta-analysis. Anaesthesia. 2014;69(10):1138–50.PubMed
56.
Mazoit JX, Samii K. Binding of propofol to blood components: implications for pharmacokinetics and for pharmacodynamics. Br J Clin Pharmacol. 1999;47(1):35–42.PubMedPubMedCentral
57.
Li R, Liu H, Dilger JP, Lin J. Effect of Propofol on breast Cancer cell, the immune system, and patient outcome. BMC Anesthesiol. 2018;18(1):77.PubMedPubMedCentral
58.
Mammoto T, Mukai M, Mammoto A, et al. Intravenous anesthetic, propofol inhibits invasion of cancer cells. Cancer Lett. 2002;184(2):165–70.PubMed
59.
Li Q, Zhang L, Han Y, Jiang Z, Wang Q. Propofol reduces MMPs expression by inhibiting NF-kappaB activity in human MDA-MB-231 cells. Biomed Pharmacother. 2012;66(1):52–6.PubMed
60.
Ecimovic P, Murray D, Doran P, Buggy DJ. Propofol and bupivacaine in breast cancer cell function in vitro - role of the NET1 gene. Anticancer Res. 2014;34(3):1321–31.PubMed
61.
Xu W, Zheng J, Bie S, et al. Propofol inhibits Wnt signaling and exerts anticancer activity in glioma cells. Oncol Lett. 2018;16(1):402–8.PubMedPubMedCentral
62.
Xing SG, Zhang KJ, Qu JH, Ren YD, Luan Q. Propofol induces apoptosis of non-small cell lung cancer cells via ERK1/2-dependent upregulation of PUMA. Eur Rev Med Pharmacol Sci. 2018;22(13):4341–9.PubMed
63.
Wang P, Chen J, Mu LH, Du QH, Niu XH, Zhang MY. Propofol inhibits invasion and enhances paclitaxel- induced apoptosis in ovarian cancer cells through the suppression of the transcription factor slug. Eur Rev Med Pharmacol Sci. 2013;17(13):1722–9.PubMed
64.
Liu Z, Zhang J, Hong G, Quan J, Zhang L, Yu M. Propofol inhibits growth and invasion of pancreatic cancer cells through regulation of the miR-21/Slug signaling pathway. Am J Transl Res. 2016;8(10):4120–33.PubMedPubMedCentral
65.
Takabuchi S, Hirota K, Nishi K, et al. The intravenous anesthetic propofol inhibits hypoxia-inducible factor 1 activity in an oxygen tension-dependent manner. FEBS Lett. 2004;577(3):434–8.PubMed
66.
Yeh CH, Cho W, So EC, et al. Propofol inhibits lipopolysaccharide-induced lung epithelial cell injury by reducing hypoxia-inducible factor-1alpha expression. Br J Anaesth. 2011;106(4):590–9.PubMed
67.
Qian J, Shen S, Chen W, Chen N. Propofol reversed hypoxia-induced docetaxel resistance in prostate cancer cells by preventing epithelial-mesenchymal Transition by inhibiting hypoxia-inducible factor 1alpha. Biomed Res Int. 2018;2018:4174232.PubMedPubMedCentral
68.
Kasuno K, Takabuchi S, Fukuda K, et al. Nitric oxide induces hypoxia-inducible factor 1 activation that is dependent on MAPK and phosphatidylinositol 3-kinase signaling. J Biol Chem. 2004;279(4):2550–8.PubMed
69.
Liu Y, Zhang N, Cao Q, Cui X, Zhou Q, Yang C. The effects of propofol on the growth behavior of hepatoma xenografts in Balb/c mice. Biomed Pharmacother. 2017;90:47–52.PubMed
70.
Franks NP, Lieb WR. Molecular and cellular mechanisms of general anaesthesia. Nature. 1994;367(6464):607–14.PubMed
71.
Schofield PR, Darlison MG, Fujita N, et al. Sequence and functional expression of the GABA A receptor shows a ligand-gated receptor super-family. Nature. 1987;328(6127):221–7.PubMed
72.
Young SZ, Bordey A. GABA’s control of stem and cancer cell proliferation in adult neural and peripheral niches. Physiology (Bethesda). 2009;24:171–85.
73.
Zhang X, Zhang R, Zheng Y, et al. Expression of gamma-aminobutyric acid receptors on neoplastic growth and prediction of prognosis in non-small cell lung cancer. J Transl Med. 2013;11:102.PubMedPubMedCentral
74.
Joseph J, Niggemann B, Zaenker KS, Entschladen F. The neurotransmitter gamma-aminobutyric acid is an inhibitory regulator for the migration of SW 480 colon carcinoma cells. Cancer Res. 2002;62(22):6467–9.PubMed
75.
Zhang D, Li X, Yao Z, Wei C, Ning N, Li J. GABAergic signaling facilitates breast cancer metastasis by promoting ERK1/2-dependent phosphorylation. Cancer Lett. 2014;348(1–2):100–8.PubMed
76.
Neman J, Termini J, Wilczynski S, et al. Human breast cancer metastases to the brain display GABAergic properties in the neural niche. Proc Natl Acad Sci U S A. 2014;111(3):984–9.PubMedPubMedCentral
77.
Takehara A, Hosokawa M, Eguchi H, et al. Gamma-aminobutyric acid (GABA) stimulates pancreatic cancer growth through overexpressing GABAA receptor pi subunit. Cancer Res. 2007;67(20):9704–12.PubMed
78.
Sizemore GM, Sizemore ST, Seachrist DD, Keri RA. GABA(A) receptor pi (GABRP) stimulates basal-like breast cancer cell migration through activation of extracellular-regulated kinase 1/2 (ERK1/2). J Biol Chem. 2014;289(35):24102–13.PubMedPubMedCentral
79.
Babateen O, Jin Z, Bhandage A, et al. Etomidate, propofol and diazepam potentiate GABA-evoked GABAA currents in a cell line derived from human glioblastoma. Eur J Pharmacol. 2015;748:101–7.PubMed
80.
Garib V, Lang K, Niggemann B, Zanker KS, Brandt L, Dittmar T. Propofol-induced calcium signalling and actin reorganization within breast carcinoma cells. Eur J Anaesthesiol. 2005;22(8):609–15.PubMed
81.
Morvan MG, Lanier LL. NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer. 2016;16(1):7–19.PubMed
82.
Kim S, Iizuka K, Aguila HL, Weissman IL, Yokoyama WM. In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proc Natl Acad Sci U S A. 2000;97(6):2731–6.PubMedPubMedCentral
83.
Ljunggren HG, Malmberg KJ. Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol. 2007;7(5):329–39.PubMed
84.
• Stollings LM, Jia LJ, Tang P, Dou H, Lu B, Xu Y. Immune modulation by volatile anesthetics. Anesthesiology. 2016;125(2):399–411A comprehensive review of the modulation of innate and adaptive immunity by inhalational anesthetics and potential mechanisms.PubMed
85.
86.
Mitsuhata H, Shimizu R, Yokoyama MM. Suppressive effects of volatile anesthetics on cytokine release in human peripheral blood mononuclear cells. Int J Immunopharmacol. 1995;17(6):529–34.PubMed
87.
Miyata T, Kodama T, Honma R, et al. Influence of general anesthesia with isoflurane following propofol-induction on natural killer cell cytotoxic activities of peripheral blood lymphocytes in dogs. J Vet Med Sci. 2013;75(7):917–21.PubMed
88.
Buckley A, McQuaid S, Johnson P, Buggy DJ. Effect of anaesthetic technique on the natural killer cell anti-tumour activity of serum from women undergoing breast cancer surgery: a pilot study. Br J Anaesth. 2014;113(Suppl 1):i56–62.PubMed
89.
Yuki K, Astrof NS, Bracken C, et al. The volatile anesthetic isoflurane perturbs conformational activation of integrin LFA-1 by binding to the allosteric regulatory cavity. FASEB J. 2008;22(12):4109–16.PubMedPubMedCentral
90.
Yuki K, Astrof NS, Bracken C, Soriano SG, Shimaoka M. Sevoflurane binds and allosterically blocks integrin lymphocyte function-associated antigen-1. Anesthesiology. 2010;113(3):600–9.PubMed
91.
Yuki K, Bu W, Xi J, Sen M, Shimaoka M, Eckenhoff RG. Isoflurane binds and stabilizes a closed conformation of the leukocyte function-associated antigen-1. FASEB J. 2012;26(11):4408–17.PubMedPubMedCentral
92.
•• Tazawa K, Koutsogiannaki S, Chamberlain M, Yuki K. The effect of different anesthetics on tumor cytotoxicity by natural killer cells. Toxicol Lett. 2017;266:23–31 Demonstrates a molecular mechanism for anesthetic modulation of antitumor NK cell cytotoxicity involving allosteric inhibition of LFA-1 by inhalational but not intravenous anesthetics.PubMed
93.
Jung S, Yuki K. Differential effects of volatile anesthetics on leukocyte integrin macrophage-1 antigen. J Immunotoxicol. 2016;13(2):148–56.PubMed
94.
Benish M, Bartal I, Goldfarb Y, et al. Perioperative use of beta-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis. Ann Surg Oncol. 2008;15(7):2042–52.PubMed
95.
Glasner A, Avraham R, Rosenne E, et al. Improving survival rates in two models of spontaneous postoperative metastasis in mice by combined administration of a beta-adrenergic antagonist and a cyclooxygenase-2 inhibitor. J Immunol. 2010;184(5):2449–57.PubMed
96.
Tai LH, de Souza CT, Belanger S, et al. Preventing postoperative metastatic disease by inhibiting surgery-induced dysfunction in natural killer cells. Cancer Res. 2013;73(1):97–107.PubMed
97.
Eddy JL, Krukowski K, Janusek L, Mathews HL. Glucocorticoids regulate natural killer cell function epigenetically. Cell Immunol. 2014;290(1):120–30.PubMedPubMedCentral
98.
Inada T, Hirota K, Shingu K. Intravenous anesthetic propofol suppresses prostaglandin E2 and cysteinyl leukotriene production and reduces edema formation in arachidonic acid-induced ear inflammation. J Immunotoxicol. 2015;12(3):261–5.PubMed
99.
Kambara T, Inada T, Kubo K, Shingu K. Propofol suppresses prostaglandin E(2) production in human peripheral monocytes. Immunopharmacol Immunotoxicol. 2009;31(1):117–26.PubMed
100.
Inada T, Yamanouchi Y, Jomura S, et al. Effect of propofol and isoflurane anaesthesia on the immune response to surgery. Anaesthesia. 2004;59(10):954–9.PubMed
101.
Ji FH, Wang YL, Yang JP. Effects of propofol anesthesia and sevoflurane anesthesia on the differentiation of human T-helper cells during surgery. Chin Med J (Engl). 2011;124(4):525–9.
102.
Ren XF, Li WZ, Meng FY, Lin CF. Differential effects of propofol and isoflurane on the activation of T-helper cells in lung cancer patients. Anaesthesia. 2010;65(5):478–82.PubMed
103.
Sullivan R, Peppercorn J, Sikora K, et al. Delivering affordable cancer care in high-income countries. Lancet Oncol. 2011;12(10):933–80.PubMed
Metadata
Title
Propofol (TIVA) Versus Volatile-Based Anesthetics: Is There Any Oncological Benefit?
Authors
Nicholas J. S. Perry
Timothy Wigmore
Publication date
01-12-2018
Publisher
Springer US
Published in
Current Anesthesiology Reports / Issue 4/2018
Electronic ISSN: 2167-6275
DOI
https://doi.org/10.1007/s40140-018-0296-z

Other articles of this Issue 4/2018

Current Anesthesiology Reports 4/2018 Go to the issue

Cancer Anesthesia (B Riedel and V Gottumukkala, Section Editors)

Transfusion Therapy: Is There a Link with Cancer Recurrence?

Cancer Anesthesia (B Riedel and V Gottumukkala, Section Editors)

Cancer Biology: a Primer for Perioperative Clinicians

Cancer Anesthesia (B Riedel and V Gottumukkala, Section Editors)

Local Anesthetics (LAs) and Cancer Cell Progression: Is There an Oncologic Protective Role for LAs in Clinical Practice?

Pain Medicine (GJ Meredith, Section Editor)

Considerations in 2017–2018 for the Use of Opioids in Non-terminal Pain

Cancer Anesthesia (B Riedel and V Gottumukkala, Section Editors)

Intensive Care Practice in the Cancer Patient Population: Special Considerations and Challenges

Cancer Anesthesia (B Riedel and V Gottumukkala, Section Editors)

Prehabilitation Prior to Major Cancer Surgery: Training for Surgery to Optimize Physiologic Reserve to Reduce Postoperative Complications